{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:47:00Z","timestamp":1759366020276,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.acuro.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T18:47:23Z","timestamp":1600195643000},"page":"586-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Avances en uro-oncolog\u00eda \u00abOncoForum\u00bb: lo mejor del 2019"],"prefix":"10.1016","volume":"44","author":[{"given":"F.","family":"G\u00f3mez-Veiga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alcaraz Asensio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Burgos Revilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"C\u00f3zar Olmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2020.06.007_bib0250","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.acuro.2015.02.004","article-title":"Avances en uro-oncolog\u00eda \u00abOncoForum\u00bb: lo mejor de 2014","volume":"39","author":"G\u00f3mez-Veiga","year":"2015","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.acuro.2020.06.007_bib0255","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.acuro.2016.03.002","article-title":"Avances en uro-oncolog\u00eda \u00abOncoForum\u00bb: lo mejor de 2015","volume":"40","author":"G\u00f3mez-Veiga","year":"2016","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.acuro.2020.06.007_bib0260","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.acuro.2018.06.001","article-title":"Avances en uro-oncolog\u00eda \u00abOncoForum\u00bb: lo mejor del 2017","volume":"42","author":"G\u00f3mez-Veiga","year":"2018","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.acuro.2020.06.007_bib0265","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1016\/S1569-9056(19)30885-1","article-title":"Active surveillance for small renal masses \u2264 2cm: Results from an Italian multi-institutional prospective protocol","volume":"18","author":"Cazzaniga","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0270","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1016\/S1569-9056(19)30887-5","article-title":"Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A retrospective cohort study","volume":"18","author":"Tan","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0275","doi-asserted-by":"crossref","first-page":"e1167","DOI":"10.1016\/S1569-9056(19)30841-3","article-title":"Techniques and outcomes of robot-assisted IVC thrombetomy in RCC","volume":"18","author":"Wang","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0280","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2020.06.007_bib0285","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2019.37.7_suppl.547","article-title":"Thirty-month follow-up of the phase iii CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"37","author":"Tannir","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0290","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2020.06.007_bib0295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0300","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.2019.37.7_suppl.575","article-title":"Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors","volume":"37","author":"Shah","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0305","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2020.06.007_bib0310","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME Randomized Clinical Trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0315","unstructured":"Ljungberg B, Albiges L, Bensalah K, Bex A, Giles RH, Hora M, et al. EAU Guidelines on Renal Cell Carcinoma 2020. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. ISBN 978-94-92671-07-3. EAU Guidelines Office, Arnhem, The Netherlands. http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/"},{"key":"10.1016\/j.acuro.2020.06.007_bib0320","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: Phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0325","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2019.37.15_suppl.4503","article-title":"CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase iii trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0330","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.acuro.2020.06.007_bib0335","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","article-title":"Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract","volume":"76","author":"Sternberg","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0340","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA4505","article-title":"EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors","volume":"37","author":"Petrylak","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0345","doi-asserted-by":"crossref","first-page":"e1131","DOI":"10.1016\/S1569-9056(19)30815-2","article-title":"Impact of the number of radical cystectomies per hospital on 90-day mortality in Spain","volume":"18","author":"Guijarro Cascales","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0350","doi-asserted-by":"crossref","first-page":"e1330","DOI":"10.1016\/S1569-9056(19)30960-1","article-title":"Period-specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care in Sweden &#x2013; a nation-wide population based study","volume":"18","author":"Liedberg","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0355","doi-asserted-by":"crossref","first-page":"e1523","DOI":"10.1016\/S1569-9056(19)31097-8","article-title":"Prostate-specific antigen (PSA) levels in men 60 to 70 years of age predict aggressive prostate cancer in the PLCO cancer screening trial: Implications for risk-stratified screening","volume":"18","author":"Berger","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0360","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2019.37.7_suppl.6","article-title":"Using PSMA (prostate-specific membrane antigen) evaluation on prostate biopsies for risk stratification at time of initial diagnosis","volume":"37","author":"Hupe","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0365","doi-asserted-by":"crossref","first-page":"e1703","DOI":"10.1016\/S1569-9056(19)31237-0","article-title":"Thirty-year nationwide population-based follow-up of men on active surveillance for prostate cancer: Who benefits the most? A state-transition analysis","volume":"18","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0370","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S1569-9056(19)30450-6","article-title":"Multiparametric magnetic resonance of the prostate during active surveillance for low-risk prostate cancer: Time to reduce the number of follow-up biopsies?","volume":"18","author":"Luzzago","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0375","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bju.15065","article-title":"Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: Are confirmatory biopsies still necessary?","volume":"126","author":"Osses","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2020.06.007_bib0380","doi-asserted-by":"crossref","first-page":"e3182","DOI":"10.1016\/S1569-9056(19)33522-5","article-title":"Magnetic resonance imaging alone should not be considered as a stand-alone test for disease reclassification of men in Active Surveillance","volume":"18","author":"Roscigno","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2020.06.007_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2019.37.7_suppl.1","article-title":"PACE: Analysis of acute toxicity in PACE-B, an international phase iii randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for locali","volume":"37","author":"Van As","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0390","doi-asserted-by":"crossref","first-page":"v883","DOI":"10.1093\/annonc\/mdz394.041","article-title":"Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis","volume":"30","author":"Vale","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0395","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.acuro.2020.06.007_bib0400","doi-asserted-by":"crossref","first-page":"v331","DOI":"10.1093\/annonc\/mdz248.008a","article-title":"Docetaxel for hormone-na\u00efve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial","volume":"30","author":"James","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0405","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2020.06.007_bib0410","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0415","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2020.06.007_bib0420","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0425","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0430","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.acuro.2020.06.007_bib0435","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0440","doi-asserted-by":"crossref","first-page":"v330","DOI":"10.1093\/annonc\/mdz248.007","article-title":"Benefit of prostate radiotherapy for patients with lymph node only or<4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE \u201cM1\/RT comparison\u201d","volume":"30","author":"Ali","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0445","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.2019.37.7_suppl.140","article-title":"ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC)","volume":"37","author":"Fizazi","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0450","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.2019.37.7_suppl.144","article-title":"Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)","volume":"37","author":"Small","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0455","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdz397","article-title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","volume":"30","author":"Small","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0460","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2020.06.007_bib0465","unstructured":"Press Note, 11\/02\/2020. XTANDI\u00ae (enzalutamide) Demonstrates significant improvement in overall survival in phase 3 PROSPER Trial of Patients with nmCRPC [consultado 15 May 2020]. Disponible en: https:\/\/www.astellas.com\/en\/news\/15586"},{"key":"10.1016\/j.acuro.2020.06.007_bib0470","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2019.37.7_suppl.228","article-title":"Results of a 50 patient single-center phase ii prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer","volume":"37","author":"Hofman","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0475","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0480","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1200\/JCO.2019.37.15_suppl.5007","article-title":"Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333\/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis","volume":"37","author":"Tombal","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2020.06.007_bib0485","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"De Wit","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2020.06.007_bib0490","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480620301534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480620301534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:37:20Z","timestamp":1759322240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480620301534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0210480620301534"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2020.06.007","relation":{},"ISSN":["0210-4806"],"issn-type":[{"type":"print","value":"0210-4806"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avances en uro-oncolog\u00eda \u00abOncoForum\u00bb: lo mejor del 2019","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}